Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Valbenazine Tosylate Patent Expiration

Valbenazine Tosylate is Used for treating Huntington's chorea and tardive dyskinesia in patients without concomitant use of strong CYP3A4 inducers. It was first introduced by Neurocrine Biosciences Inc in its drug Ingrezza on Apr 11, 2017. Another drug containing Valbenazine Tosylate is Ingrezza Sprinkle. 3 different companies have introduced drugs containing Valbenazine Tosylate.


Valbenazine Tosylate Patents

Given below is the list of patents protecting Valbenazine Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ingrezza US10940141 Methods for the administration of certain VMAT2 inhibitors Aug 10, 2040 Neurocrine
Ingrezza Sprinkle US10940141 Methods for the administration of certain VMAT2 inhibitors Aug 10, 2040 Neurocrine
Ingrezza US11026931 Methods for the administration of certain VMAT2 inhibitors Aug 14, 2039 Neurocrine
Ingrezza Sprinkle US11026931 Methods for the administration of certain VMAT2 inhibitors Aug 14, 2039 Neurocrine
Ingrezza US11654142 Methods for the administration of certain VMAT2 inhibitors Nov 14, 2038 Neurocrine
Ingrezza Sprinkle US11654142 Methods for the administration of certain VMAT2 inhibitors Nov 14, 2038 Neurocrine
Ingrezza US11026939 High dosage valbenazine formulation and compositions, methods, and kits related thereto Sep 18, 2038 Neurocrine
Ingrezza US11311532 High dosage valbenazine formulation and compositions, methods, and kits related thereto Sep 18, 2038 Neurocrine
Ingrezza Sprinkle US11026939 High dosage valbenazine formulation and compositions, methods, and kits related thereto Sep 18, 2038 Neurocrine
Ingrezza Sprinkle US11311532 High dosage valbenazine formulation and compositions, methods, and kits related thereto Sep 18, 2038 Neurocrine
Ingrezza US10857137 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US10857148 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US10874648 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US10912771 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US10952997 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US10993941 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US11040029 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US11439629 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US10857137 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US10857148 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US10874648 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US10912771 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US10952997 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US10993941 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US11040029 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza Sprinkle US11439629 Methods for the administration of certain VMAT2 inhibitors Oct 10, 2037 Neurocrine
Ingrezza US10906902 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Dec 22, 2036 Neurocrine
Ingrezza US10906903 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Dec 22, 2036 Neurocrine
Ingrezza US10919892 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Dec 22, 2036 Neurocrine
Ingrezza Sprinkle US10906902 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Dec 22, 2036 Neurocrine
Ingrezza Sprinkle US10906903 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Dec 22, 2036 Neurocrine
Ingrezza Sprinkle US10919892 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Dec 22, 2036 Neurocrine
Ingrezza US10065952 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza US10844058 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza US10851103 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza US10851104 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza Sprinkle US10065952 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza Sprinkle US10844058 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza Sprinkle US10851103 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza Sprinkle US10851104 Valbenazine salts and polymorphs thereof Oct 28, 2036 Neurocrine
Ingrezza US8039627 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto Apr 11, 2031 Neurocrine
Ingrezza Sprinkle US8039627 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto Apr 11, 2031 Neurocrine
Ingrezza US8357697 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto Nov 08, 2027 Neurocrine
Ingrezza Sprinkle US8357697 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto Nov 08, 2027 Neurocrine



Valbenazine Tosylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Valbenazine Tosylate Generic API Manufacturers

Several generic applications have been filed for Valbenazine Tosylate. The first generic version for Valbenazine Tosylate was by Lupin Ltd and was approved on Apr 5, 2024. And the latest generic version is by Zydus Lifesciences Global Fze and was approved on Aug 7, 2024.

Given below is the list of companies who have filed for Valbenazine Tosylate generic, along with the locations of their manufacturing plants worldwide.